Advertisement

Expert Point of View: Heinz-Josef Lenz, MD


Advertisement
Get Permission

Heinz-Josef Lenz, MD

Heinz-Josef Lenz, MD

Heinz-Josef Lenz, MD, of the University of Southern California in Los Angeles, said the results of the ONO-4538 trial were impressive in light of this challenging patient population. “You see a significant benefit in a highly refractory gastric cancer population,” he said.

Dr. Lenz cautioned: “Don’t get stuck on the median, because the median did not give the full benefit. You see a continuous separation of the survival curves, and as you know, the hazard ratio is the combined differences of both curves over the whole course of ­survival—the cumulative effect.”

Future studies should focus on identifying subgroups of patients whose response to nivolumab drove the overall results of ONO-4538, Dr. Lenz said. ■

Disclosure: Dr. Lenz reported no potential conflicts of interest.


Error loading Partial View script (file: ~/Views/MacroPartials/TAP Related Articles.cshtml)
Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.